Search Results for: Clinical Roundup
-
Clinic Roundup
The analyses included the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and in NRAS, collectively referred to as RAS...Additional edata will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago...ACT is currently enrolling patients in three clinical trials in the U.SBioWorld Today | Friday, May 17, 2013 -
Clinic Roundup
Sangamo BioSciences Inc., of Richmond, Calif., said it presented new clinical data, which demonstrated that SB-728-T treatment resulted in a reduction in the HIV reservoir in HIV-infected subjects, at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City...HIV-infected subjects enrolled in an ongoing SB-728-902 clinical trial (Cohorts 1-3) received a single infusion of SB-728-T, which resulted in a durable increase in total CD4 T-cells driven by increased ZFNBioWorld Today | Thursday, May 16, 2013 -
Clinic Roundup
The PROCEED (PROve Clinical Efficacy and Effect of Delafloxacin) study is designed to test delafloxacin 300 mg, given intravenously every 12 hours, compared to vancomycin 15 mg/kg plus aztreonam 2 g I.V., also given every 12 hours...The study includes clinical and microbiological endpoints to assess the efficacy...Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II results published in the Journal of Clinical Oncology showed that HDAC inhibitor entinostat extended both progression-freeBioWorld Today | Wednesday, May 15, 2013 -
Washington Roundup
With an eye on streamlining the review of clinical trials with low biosafety risks, the National Institutes of Health's Office of Biotechnology Activities is proposing a revision to its guidelines for research involving recombinant or synthetic nucleic acid moleculesBioWorld Today | Wednesday, May 15, 2013 -
Financings Roundup
Funds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programsBioWorld Today | Wednesday, May 15, 2013 -
Clinic Roundup
Mirna Therapeutics Inc., of Austin, Texas, has initiated a Phase I study of MRX34, the first miRNA to advance to a clinical trial for cancerBioWorld Today | Tuesday, May 14, 2013 -
Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic
is more than doubling its cash position with a $30 million registered direct offering, with proceeds to fund R&D activities, namely clinical development of DX-2930, a drug slated to start clinical development for prophylactic use in hereditary angioedema (HAE...Shares of the company (NASDAQ:MNOV) gained 58 cents, or 16.5 percent, to close Monday at $4.10.By Jennifer Boggs | BioWorld Today | Tuesday, May 14, 2013 -
Financings Roundup
Net proceeds are expected to total about $16.1 million and will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as clinical trials of its OMS103HP, PDE10, MASP-2 and PDE7 programsBioWorld Today | Monday, May 13, 2013 -
Pharma: Clinic Roundup
Eisai Inc., of Woodcliff Lake, N.J., said antiepileptic drug Fycompa (perampanel) showed a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy, according to two new analyses of early clinical experienceBioWorld Today | Friday, May 10, 2013 -
Isis Peers Beyond Kynamro, Seeks $171M for Pipeline
clinical development plan and financial terms relating to ISIS-TTRRx to reflect an accelerated development plan for that antisense drug...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 monthsBy Marie Powers | BioWorld Today | Friday, May 10, 2013 -
Receptos Prices Solid IPO, Raises $72.8M for Pipeline
The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Chardan Capital Markets LLC acted as exclusive placement agent for the offering.By Catherine Shaffer | BioWorld Today | Friday, May 10, 2013 -
Committee Looks for the Bright Line in Compounding
There may be value in discussing the benefit-risk framework at end-of-Phase II meetings, in order to ensure alignment on identified and potential risks and benefits, critical efficacy and safety assessments, and risk mitigation strategies in Phase III clinical trials," PhRMA noted...Imposition of a de-facto comparative effectiveness standard would make many worthy drug development programs infeasible," the organization said.By Mari Serebrov | BioWorld Today | Friday, May 10, 2013 -
Clinic Roundup
Data demonstrated that EBI-005 was safe and well tolerated in both preclinical testing and in a clinical Phase Ia study in healthy volunteers...These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013BioWorld Today | Thursday, May 9, 2013 -
Lumena Large: $23M Series A Funds Phase II Cholestatic Bid
The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Also in the pipeline: Lumena has licensed the patent rights and a package of clinical and non-clinical data for LUM002, another inhibitor of ASBT, also previously in development at the Phase I stage as a cholesterol-lowering agent by Paris-based Sanofi SA...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this yearBy Randy Osborne | BioWorld Today | Thursday, May 9, 2013 -
Increased Demand for Pediatric Trials Leads to BIO Initiative
Using ViS' online analytics platform, the initiative is expected to reduce the barriers to global pediatric clinical research by helping drugmakers identify patients, enabling streamlined trial enrollment and site selection...Eventually, it could be used to find research centers, staffing talent and other resources needed to conduct a pediatric clinical trial in a specific region...To get FDA authorization to charge for an investigative drug or for an unapproved use of an approved drug in a clinicalBy Mari Serebrov | BioWorld Today | Thursday, May 9, 2013 -
Pharma: Clinic Roundup
The study, dubbed Gammaglobulin Alzheimer's Partnership, was conducted in collaboration with the Alzheimer's Disease Cooperative Study, a clinical trial consortium supported by the National Institute on AgingBioWorld Today | Wednesday, May 8, 2013 -
Latest Astellas, Drais Spinout, Tacurion Launches with $15M
spun out in 2011, and Flexion Therapeutics Inc., of Woburn, Mass., founded by veterans of Eli Lilly and Co.'s Chorus division to advance abandoned early clinical programs through proof of concept. (See BioWorld Today, Feb. 1, 2010, and July 28, 2011.) The $15 million investment in Tacurion will support a Phase II proof-of-concept trial for the drug that should take 18 months to two years to complete...Portola, which seeks a listing on Nasdaq under the ticker "PTLA," filed for the IPO last monthBy Catherine Shaffer | BioWorld Today | Wednesday, May 8, 2013 -
More States Are Saying No to Biosimilar Safeguards
An interchangeable biologic is expected to produce the same clinical results as the reference drug in any given patient...CER Projects Funded The Patient-Centered Outcomes Research Institute approved 51 new awards, totaling $88.6 million over three years, to fund comparative clinical effectiveness research (CER) projects that fall under the first four areas of its research agenda...Editor's note: For a copy of BioWorld's new biosimilars report, please contact the BioWorld Data account managers forBy Mari Serebrov | BioWorld Today | Wednesday, May 8, 2013 -
Clinic Roundup
CytRx Corp., of Los Angeles, said the independent data safety monitoring committee overseeing the company's international Phase IIb trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion...The NH004-3 clinical trial is a double-blind, placebo-controlled, randomized, crossover, multicenter study comparing NH004 and placebo thin films in Parkinson's disease patient complaining ofBioWorld Today | Tuesday, May 7, 2013 -
Arrowhead Bolsters Balance Sheet, Adds $36M for Pipeline
shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.By Jennifer Boggs | BioWorld Today | Tuesday, May 7, 2013
Category
Current Filters
- xNOT Life Sciences
Related Keywords
Categories
- x BioWorld Today (2315)
- x BioWorld International (44)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.